Clinical trial
Phase 1/2a, Randomized, Double-Blind Placebo-Controlled, Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Response of PB1023 Injection Following Single and Multiple Ascending Subcutaneous Doses in Adult Subjects With Type 2 Diabetes Mellitus (T2DM)
NCT01236404 is registered in ClinicalTrials.gov with PhaseBio Pharmaceuticals Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 1/2a, Randomized, Double-Blind Placebo-Controlled, Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Response of PB1023 Injection Following Single and Multiple Ascending Subcutaneous Doses in Adult Subjects With Type 2 Diabetes Mellitus (T2DM)
- Lead sponsor
- PhaseBio Pharmaceuticals Inc.
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- November 30, 2010
- Completion date
- November 30, 2011
- Enrollment
- 80 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.